Of 321 adenocarcinomas, membranous or cytoplasmic HER2 expression was classified as negative in 192 cases (59.8%), low in 98 (30.5%), intermediate in 25 (7.8%), and high in 6 (1.9%) by the H-scoring method (Fig 1). This evidence concerns the gene ERBB2 and adenocarcinoma.